The Current Ratio as of September 2024 (TTM) for Trevi Therapeutics, Inc. (TRVI) is 10.68

According to Trevi Therapeutics, Inc.’s latest financial reports and current stock price. The company's current Current Ratio is 10.68. This represents a change of -26.87% compared to the average of 14.61 of the last 4 quarters.

Trevi Therapeutics, Inc. (TRVI) Historical Current Ratio (quarterly & annually)

How has TRVI Current Ratio performed in the past?

The mean historical Current Ratio of Trevi Therapeutics, Inc. over the last ten years is 7.19. The current 10.68 Current Ratio has changed 14.76% with respect to the historical average. Over the past ten years (40 quarters), TRVI's Current Ratio was at its highest in in the June 2023 quarter at 21.06. The Current Ratio was at its lowest in in the March 2018 quarter at 0.

Trevi Therapeutics, Inc. (TRVI) Current Ratio by Quarter and Year

Discovering the peaks and valleys of Trevi Therapeutics, Inc. Current Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Trevi Therapeutics, Inc. (TRVI) Average Current Ratio

How has TRVI Current Ratio performed in the past?

The current Current Ratio of Trevi Therapeutics, Inc. (TRVI) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages

Trevi Therapeutics, Inc. (TRVI) Current Ratio vs. Peers

How is TRVI’s Current Ratio compared to its peers?

Trevi Therapeutics, Inc.’s Current Ratio is greater than aTyr Pharma, Inc. (6.07), greater than Cue Biopharma, Inc. (2.06), greater than AN2 Therapeutics, Inc. (10.61), greater than BioAtla, Inc. (3.81), greater than Spero Therapeutics, Inc. (2.68), greater than Bolt Biotherapeutics, Inc. (4.28), greater than Coherus BioSciences, Inc. (1.21), greater than Gracell Biotechnologies Inc. (7.73), less than Neoleukin Therapeutics, Inc. (15.33), greater than Foghorn Therapeutics Inc. (5.69), greater than C4 Therapeutics, Inc. (5.09), less than Cyteir Therapeutics, Inc. (21.89), greater than Prelude Therapeutics Incorporated (7.83), less than Rezolute, Inc. (11.82), greater than Lyra Therapeutics, Inc. (3.60), greater than SQZ Biotechnologies Company (1.37), less than Protara Therapeutics, Inc. (16.33), greater than TRACON Pharmaceuticals, Inc. (0.66), less than Seer, Inc. (17.59), less than ORIC Pharmaceuticals, Inc. (15.08), greater than Anebulo Pharmaceuticals, Inc. (5.32), less than Cullinan Oncology, Inc. (28.87),

Build a custom stock screener for Trevi Therapeutics, Inc. (TRVI) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Trevi Therapeutics, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Trevi Therapeutics, Inc. (TRVI) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Trevi Therapeutics, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.